Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: A retrospective analysis

Elena Collovà, Antonella Ferzi, Giuseppa Scandurra, Gaetano Aurilio, Valter Torri, Luca Porcu, Maria Vita Sanò, Eleonora Taibi, Jennifer Foglietta, Daniele Generali, Daniele Andreis, Maria Chiara Dazzani, Annalisa Bramati, Ilaria Marcon, Francesco Atzori, Saverio Cinieri, Luca Tondulli, Donatella Grasso, Franco Nolè, Maria Cristina PetrellaStefania Gori, Nicla La Verde

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Aims and background: The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. The aim of the study was to describe the efficacy and safety of a firstline treatment in unselected metastatic HER2-positive breast cancer patients, treated according to clinical practice.

Methods: From 2000 to 2009, we conducted a retrospective multi-institutional analysis of 182 consecutive patients with HER2-positive metastatic breast cancer who underwent first-line treatment with trastuzumab. The primary end points were progressionfree survival and overall survival; the secondary end points were survival after progression in patients treated with second-line chemotherapy with or without trastuzumab and safety. A total of 172 patients were analyzed.

Results: Median progression-free survival and overall survival were 1.2 (95% CI, 1.1-1.4) and 4.4 years (95% CI, 3.6-5.4), respectively. For 100 patients who received secondline chemotherapy, median survival after progression was significantly longer in those who also received trastuzumab: 2.8 (95% CI, 2.1-4.0) versus 1.2 years (95% CI, 0.6-1.9).

Conclusions: Although based on retrospective data, the study confirms the role of trastuzumab as first-line treatment in metastatic breast cancer outside of a controlled trial. Moreover, information obtained on the use of trastuzumab beyond disease progression supports its use in this setting.

Original languageEnglish
Title of host publicationTumori
PublisherIl Pensiero Scientifico Editore s.r.l.
Pages426-431
Number of pages6
Volume100
Edition4
DOIs
Publication statusPublished - Jul 1 2014

Fingerprint

Breast Neoplasms
Survival
Drug Therapy
Disease-Free Survival
Safety
Disease Progression
Trastuzumab
Therapeutics
Retrospective Studies

Keywords

  • HER2-positive metastatic breast cancer
  • Trastuzumab

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Collovà, E., Ferzi, A., Scandurra, G., Aurilio, G., Torri, V., Porcu, L., ... La Verde, N. (2014). Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: A retrospective analysis. In Tumori (4 ed., Vol. 100, pp. 426-431). Il Pensiero Scientifico Editore s.r.l.. https://doi.org/10.1700/1636.17902

Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer : A retrospective analysis. / Collovà, Elena; Ferzi, Antonella; Scandurra, Giuseppa; Aurilio, Gaetano; Torri, Valter; Porcu, Luca; Sanò, Maria Vita; Taibi, Eleonora; Foglietta, Jennifer; Generali, Daniele; Andreis, Daniele; Dazzani, Maria Chiara; Bramati, Annalisa; Marcon, Ilaria; Atzori, Francesco; Cinieri, Saverio; Tondulli, Luca; Grasso, Donatella; Nolè, Franco; Petrella, Maria Cristina; Gori, Stefania; La Verde, Nicla.

Tumori. Vol. 100 4. ed. Il Pensiero Scientifico Editore s.r.l., 2014. p. 426-431.

Research output: Chapter in Book/Report/Conference proceedingChapter

Collovà, E, Ferzi, A, Scandurra, G, Aurilio, G, Torri, V, Porcu, L, Sanò, MV, Taibi, E, Foglietta, J, Generali, D, Andreis, D, Dazzani, MC, Bramati, A, Marcon, I, Atzori, F, Cinieri, S, Tondulli, L, Grasso, D, Nolè, F, Petrella, MC, Gori, S & La Verde, N 2014, Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: A retrospective analysis. in Tumori. 4 edn, vol. 100, Il Pensiero Scientifico Editore s.r.l., pp. 426-431. https://doi.org/10.1700/1636.17902
Collovà E, Ferzi A, Scandurra G, Aurilio G, Torri V, Porcu L et al. Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: A retrospective analysis. In Tumori. 4 ed. Vol. 100. Il Pensiero Scientifico Editore s.r.l. 2014. p. 426-431 https://doi.org/10.1700/1636.17902
Collovà, Elena ; Ferzi, Antonella ; Scandurra, Giuseppa ; Aurilio, Gaetano ; Torri, Valter ; Porcu, Luca ; Sanò, Maria Vita ; Taibi, Eleonora ; Foglietta, Jennifer ; Generali, Daniele ; Andreis, Daniele ; Dazzani, Maria Chiara ; Bramati, Annalisa ; Marcon, Ilaria ; Atzori, Francesco ; Cinieri, Saverio ; Tondulli, Luca ; Grasso, Donatella ; Nolè, Franco ; Petrella, Maria Cristina ; Gori, Stefania ; La Verde, Nicla. / Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer : A retrospective analysis. Tumori. Vol. 100 4. ed. Il Pensiero Scientifico Editore s.r.l., 2014. pp. 426-431
@inbook{9b7f12fe3d224422a173277bbc1824e9,
title = "Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer: A retrospective analysis",
abstract = "Aims and background: The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. The aim of the study was to describe the efficacy and safety of a firstline treatment in unselected metastatic HER2-positive breast cancer patients, treated according to clinical practice.Methods: From 2000 to 2009, we conducted a retrospective multi-institutional analysis of 182 consecutive patients with HER2-positive metastatic breast cancer who underwent first-line treatment with trastuzumab. The primary end points were progressionfree survival and overall survival; the secondary end points were survival after progression in patients treated with second-line chemotherapy with or without trastuzumab and safety. A total of 172 patients were analyzed.Results: Median progression-free survival and overall survival were 1.2 (95{\%} CI, 1.1-1.4) and 4.4 years (95{\%} CI, 3.6-5.4), respectively. For 100 patients who received secondline chemotherapy, median survival after progression was significantly longer in those who also received trastuzumab: 2.8 (95{\%} CI, 2.1-4.0) versus 1.2 years (95{\%} CI, 0.6-1.9).Conclusions: Although based on retrospective data, the study confirms the role of trastuzumab as first-line treatment in metastatic breast cancer outside of a controlled trial. Moreover, information obtained on the use of trastuzumab beyond disease progression supports its use in this setting.",
keywords = "HER2-positive metastatic breast cancer, Trastuzumab",
author = "Elena Collov{\`a} and Antonella Ferzi and Giuseppa Scandurra and Gaetano Aurilio and Valter Torri and Luca Porcu and San{\`o}, {Maria Vita} and Eleonora Taibi and Jennifer Foglietta and Daniele Generali and Daniele Andreis and Dazzani, {Maria Chiara} and Annalisa Bramati and Ilaria Marcon and Francesco Atzori and Saverio Cinieri and Luca Tondulli and Donatella Grasso and Franco Nol{\`e} and Petrella, {Maria Cristina} and Stefania Gori and {La Verde}, Nicla",
year = "2014",
month = "7",
day = "1",
doi = "10.1700/1636.17902",
language = "English",
volume = "100",
pages = "426--431",
booktitle = "Tumori",
publisher = "Il Pensiero Scientifico Editore s.r.l.",
edition = "4",

}

TY - CHAP

T1 - Efficacy of trastuzumab in unselected patients with HER2-positive metastatic breast cancer

T2 - A retrospective analysis

AU - Collovà, Elena

AU - Ferzi, Antonella

AU - Scandurra, Giuseppa

AU - Aurilio, Gaetano

AU - Torri, Valter

AU - Porcu, Luca

AU - Sanò, Maria Vita

AU - Taibi, Eleonora

AU - Foglietta, Jennifer

AU - Generali, Daniele

AU - Andreis, Daniele

AU - Dazzani, Maria Chiara

AU - Bramati, Annalisa

AU - Marcon, Ilaria

AU - Atzori, Francesco

AU - Cinieri, Saverio

AU - Tondulli, Luca

AU - Grasso, Donatella

AU - Nolè, Franco

AU - Petrella, Maria Cristina

AU - Gori, Stefania

AU - La Verde, Nicla

PY - 2014/7/1

Y1 - 2014/7/1

N2 - Aims and background: The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. The aim of the study was to describe the efficacy and safety of a firstline treatment in unselected metastatic HER2-positive breast cancer patients, treated according to clinical practice.Methods: From 2000 to 2009, we conducted a retrospective multi-institutional analysis of 182 consecutive patients with HER2-positive metastatic breast cancer who underwent first-line treatment with trastuzumab. The primary end points were progressionfree survival and overall survival; the secondary end points were survival after progression in patients treated with second-line chemotherapy with or without trastuzumab and safety. A total of 172 patients were analyzed.Results: Median progression-free survival and overall survival were 1.2 (95% CI, 1.1-1.4) and 4.4 years (95% CI, 3.6-5.4), respectively. For 100 patients who received secondline chemotherapy, median survival after progression was significantly longer in those who also received trastuzumab: 2.8 (95% CI, 2.1-4.0) versus 1.2 years (95% CI, 0.6-1.9).Conclusions: Although based on retrospective data, the study confirms the role of trastuzumab as first-line treatment in metastatic breast cancer outside of a controlled trial. Moreover, information obtained on the use of trastuzumab beyond disease progression supports its use in this setting.

AB - Aims and background: The addition of trastuzumab to chemotherapy for HER2-positive metastatic breast cancer has significantly improved progression-free survival and overall survival, although most patients develop resistance or have a primarily resistant disease. The aim of the study was to describe the efficacy and safety of a firstline treatment in unselected metastatic HER2-positive breast cancer patients, treated according to clinical practice.Methods: From 2000 to 2009, we conducted a retrospective multi-institutional analysis of 182 consecutive patients with HER2-positive metastatic breast cancer who underwent first-line treatment with trastuzumab. The primary end points were progressionfree survival and overall survival; the secondary end points were survival after progression in patients treated with second-line chemotherapy with or without trastuzumab and safety. A total of 172 patients were analyzed.Results: Median progression-free survival and overall survival were 1.2 (95% CI, 1.1-1.4) and 4.4 years (95% CI, 3.6-5.4), respectively. For 100 patients who received secondline chemotherapy, median survival after progression was significantly longer in those who also received trastuzumab: 2.8 (95% CI, 2.1-4.0) versus 1.2 years (95% CI, 0.6-1.9).Conclusions: Although based on retrospective data, the study confirms the role of trastuzumab as first-line treatment in metastatic breast cancer outside of a controlled trial. Moreover, information obtained on the use of trastuzumab beyond disease progression supports its use in this setting.

KW - HER2-positive metastatic breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84908154651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908154651&partnerID=8YFLogxK

U2 - 10.1700/1636.17902

DO - 10.1700/1636.17902

M3 - Chapter

C2 - 25296592

AN - SCOPUS:84908154651

VL - 100

SP - 426

EP - 431

BT - Tumori

PB - Il Pensiero Scientifico Editore s.r.l.

ER -